Nightstar Files SEC Paperwork for Initial Public Offering

September 1, 2017: By Jon Swedien

Nightstar TherapeuticsNightstar Therapeutics Limited has filed a registration statement with the US Securities and Exchange Commission for a proposed initial public offering in the US of its American depositary shares (ADSs) representing ordinary shares, the company announced Aug. 31.

Nightstar is a clinical-stage gene therapy company focused on novel one-time treatments for patients with rare inherited retinal diseases that would otherwise progress to blindness.

All shares to be sold in the offering will be offered by Nightstar, the company said.

The number of shares and price range have not been set, Nightstar said.

The company has applied to list its shares on the NASDAQ Global Market under the ticker symbol “NITE.”

Nightstar expects its lead product candidate, NSR-REP1, to begin a Phase III trial for choroideremia in the the first half of 2018.

The company also has an ongoing Phase I/II clinical trial for NSR-RPGR, a proposed treatment for X-linked retinitis pigmentosa.

In addition, Nightstar has a Phase I/II clinical trial planned for late 2018 for a gene therapy candidate for an inherited form of macular dystrophy.

In June, Nightstar raised $45 million in a Series C financing.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022